跳到正文
Brand AI

飞利浦伟康

争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 2 条

  1. 2022

    FDA建议优先为高风险患者提供飞利浦呼吸机召回替换设备

    整改

    FDA建议飞利浦呼吸机优先为因继续使用或停止使用召回产品而面临较高健康风险的患者提供替换设备。FDA表示，先到先得的替换方式可能无法应对部分患者的健康风险。

    来源摘录

    • On March 14, 2022, the US Food and Drug Administration (FDA) updated its frequently asked questions about the Philips Respironics CPAP, BiPAP, and ventilator recall to include information about Philips Respironics’ prioritization strategy for replacement devices.
    • The FDA has recommended Philips Respironics implement a prioritization approach that ensures patients who are most vulnerable to poor healthcare outcomes with continued use or ceasing use of the recalled products receive replacement devices as quickly as possible.
    • The administration notes that a first-come, first-served replacement strategy may not address health risks for some patients.
    来源

  2. 2021

    泡沫降解与呼吸设备召回

    飞利浦伟康在识别到聚酯基聚氨酯泡沫降解的潜在危害后，召回了某些CPAP、BiPAP和呼吸机设备。监管机构、患者、记者和诉讼当事人随后审查了公司的投诉报告、风险评估、沟通和补救措施。关于伤害和疾病的索赔已通过多个法律程序进行争议和裁决；召回本身及相关监管调查结果已确定。

    来源